Cingulate (CINGW) Change in Accured Expenses (2021 - 2025)
Cingulate's (CINGW) quarterly Change in Accured Expenses came in at $1.3 million in Q4 2025, up 30.94% on a YoY basis from $1.0 million in Q4 2024, and up 20.12% quarter-over-quarter from $1.1 million in Q3 2025.
Analysis
Cingulate (CINGW) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Change in Accured Expenses for 5 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 30.94% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 132.33% YoY), and the FY2025 full-year result was $1.5 million, up 132.33% from the prior year.
- Change in Accured Expenses grew to $1.3 million in Q4 2025 per CINGW's latest filing, from $1.1 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.7 million in Q4 2023 and bottomed at -$5.0 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $79356.4 across 5 years, with a median of $457992.5 in 2022.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 519.28% in 2023, then slumped 1292.24% in 2024.
- Over 5 years, Change in Accured Expenses stood at -$3.4 million in 2021, then soared by 117.44% to $593543.0 in 2022, then soared by 519.28% to $3.7 million in 2023, then slumped by 72.75% to $1.0 million in 2024, then jumped by 30.94% to $1.3 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $1.3 million, $1.1 million, and -$82352.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 55.78 Mn |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | -204.33 Mn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | -4.00 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | -82,352.00 |
| Mar 31, 2025 | -852,914.00 |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | -404,330.00 |
| Jun 30, 2024 | -142,889.00 |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | 3.68 Mn |
| Sep 30, 2023 | 544,458.00 |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | -358,777.00 |
| Dec 31, 2022 | 593,543.00 |
| Sep 30, 2022 | 469,611.00 |
| Jun 30, 2022 | -718,523.00 |
| Mar 31, 2022 | 446,374.00 |
| Dec 31, 2021 | -3.40 Mn |
| Sep 30, 2021 | 1.54 Mn |
| Jun 30, 2021 | 799,362.00 |
| Mar 31, 2021 | -257,690.00 |